Skip to main content
  • Meet our 2018-2019 T32 Fellows

    Meet our 2019-2020 T32 Fellows

Active Studies

  • MF-59 and ASO3-adjuvanted H5N8 influenza vaccines in healthy adults
  • Meningitis vaccine in pregnant women (domestic and international)
  • Tdap vaccine in pregnant women in Mali
  • Pharmacokinetic study of vancomycin in critically ill infants and children
  • Safety and immunogenicity of dmLT by different routes in Bangladesh
  • Mupirocin in elimination of S. aureus colonization in neonates
  • Malaria vaccine trials
    • Phase I dose escalation study of recombinant circumsporozoite protein (rCSP) antigen in healthy, malaria-naïve, adults (domestic)

    • PfSPZ challenge study to assess safety, tolerability, immunogenicity, and efficacy of PfSPZ-CVac in Malian adults

    Learn More about active studies

  • Phase I Challenge Study to Evaluate Safety, Immunogenicity, and Efficacy of a Malaria Vaccine (rCSP Adjuvanted with GLA-SE), in Healthy Adults*
  • Phase II Trial to Evaluate the Safety and Immunogenicity of MENVEO® in Pregnant Women
  • Lab Assays for Phase 1 Study in Healthy Adults to Determine the Safety and Immunogenicity of an Attenuated Recombinant dmLT from ETEC Vaccine
  • Phase I Study to Evaluate the Safety and Immunogenicity of dmLT from ETEC by Oral, Sublingual, or Intradermal Vaccination in Adults in an Endemic Area
  • Establishment of Central Facilities to Analyze Samples for Circulating Cytokines and Activation and/or Increase in Subpopulations of Natural Immune Cells, and T and B Cells
  • Phase II Trial to Evaluate the Safety, Immunogenicity and Effect on Infant Immune Responses of a Single Dose of Tdap in Pregnant Women in Africa
  • Safety, Tolerability, Immunogenicity and Protective Efficacy against Naturally-Transmitted Malaria of PfSPZ Challenge Administered by Direct Venous Inoculation under PfSPZ-CVac in Malian Adults*
  • Phase I Trial in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of  A/H5N8 Vaccine Administered at Different Dosages With or Without AS03 or MF59 Adjuvants
  • Population PK Study to Evaluate the Dose Needed to Achieve AUC24/MIC >/ 400 in PICU Patients on Vancomycin
  • Sub-study to Evaluate the Anti-Hemagglutinin Antibody Responses by Protein Microarrray in Subjects Who Received an A/H5N1 vaccine With or Without AS03 and MF59 Adjuvants
  • Phase 4 Trial to Evaluate the Efficacy of an Injectable Free Delamanid Containing Regimen for the Treatment of MDR TB
  • Phase II Study in Healthy Adults to Assess the Sequential or Simultaneous Intramuscular Administration of an AS03-adjuvanted A/H7N9 Inactivated Influenza Vaccine with Seasonal Influenza Vaccine
  • Phase II Study in Healthy Adults to Assess the Safety, Reactogenicity and Immunogenicity of A/H7N9 Inactivated Influenza Vaccine Administered IM With or Without AS03 Adjuvant
  • Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered IM zWith or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
  • Phase II Trial to Evaluate the Effects of a Single Dose of Tdap in Pregnant Women in Africa
  • A Sub-study to Evaluate Epitope Mapping of Antibodies Elicited by Controlled Human Malaria Infection, Vaccination, and Natural Infection with Plasmodium falciparum Malaria in studies with * above.